Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.

In addition, at day 56, there was a statistically significant increase in cholesterol efflux capacity in SLE subjects treated with tofacitinib ( P = 0.002, 95% CI: 0.04–0.16) and a nonsignificant trend when compared to placebo ( P = 0.08, 95% CI: −0.01, 0.24) (Supplementary Fig. 5e ).

also in 5,406 other papers

Even though these changes did not reach statistical significance (probably due to the small sample size) yet the extent of change in a short duration is impressive and requires further exploring.

also in 111,027 other papers